Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.

McManus, P; Birkett, D J; Dudley, J; Stevens, A

McManus, P; Birkett, D J; Dudley, J; Stevens, A.

Affiliation

McManus P; Drug Utilisation Sub-Committee MDP 83, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, Australia. peter.mcmanus@health.gov.au

Pharmacoepidemiol Drug Saf ; 10(4): 295-300, 2001.

Article in En | MEDLINE | ID: mdl-11760489

Subject(s)

Drugs, Generic/economics; Insurance, Pharmaceutical Services/economics; National Health Programs/economics; Anti-Ulcer Agents/economics; Antidepressive Agents, Second-Generation/economics; Australia; Cohort Studies; Drug Costs; Drug Prescriptions/economics; Drug Prescriptions/statistics & numerical data; Fluoxetine/economics; Humans; Ranitidine/economics

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Drugs, Generic / Insurance, Pharmaceutical Services / National Health Programs Type of study: Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies Limits: Humans Country/Region as subject: Oceania Language: En Journal: Pharmacoepidemiol Drug Saf Journal subject: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Year: 2001 Document type: Article Affiliation country: Australia

Search on Google

Add to My VHL

XML

PubMed Links